Odimma Therapeutics (Strasbourg, France) is delighted to announce having been selected to be one of the five start-up companies financed by the second edition of the WiClub Health.
WiClub Health is a funding program supported by Wiseed, the French leading crowd funding organization in collaboration with Semia/Quest For Health the major French incubator in health technologies.
Jessica Matta, CEO, said “we are extremely proud to participate as a finalist into this high-level crowd-funding event. This selection recognizes Odimma Therapeutic’s maturity and the potential of its innovative personalized immunotherapy platform”.
Odimma’s current funding operations are aimed at financing the last regulatory milestones in order to move toward the clinic with the first in man clinical trial planned in 2023.
To contribute, you can directly click on the link below:
About Odimma Therapeutics
Odimma Therapeutics (Strasbourg – France) is a European biotech company with a unique approach in active personalized cancer immunotherapy. By harnessing the ability of the patient’s own immune system to specifically recognize specific markers displayed by the tumor, also called neoantigens, Odimma Therapeutics has designed a potent next-generation precision immunotherapy platform able induce a powerful cellular immune response against specific tumours markers as well as a strong anti-tumoral effect in several aggressive models such as melanoma, colorectal and breast cancer. By design the personalized product can be produced in a short period of time with a favourable economic profile, with no limits in the number of neoantigens to be targeted thus maximise patient benefit.
To follow our news, you can also connect to our Linkedin page: